Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRXNASDAQ:ADILNASDAQ:CYCCNASDAQ:GLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRXAcelRx Pharmaceuticals$0.77$0.43▼$2.78$14.58M0.52137,683 shs243,500 shsADILAdial Pharmaceuticals$0.66-4.1%$0.69$0.57▼$3.00$5.22M1.211.11 million shs470,025 shsCYCCCyclacel Pharmaceuticals$1.65+3.1%$3.41$1.36▼$49.34$25.39M0.52112,110 shs229,083 shsGLMDGalmed Pharmaceuticals$1.44+0.7%$1.39$1.15▼$23.80$2.38M0.491.30 million shs179,493 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRXAcelRx Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ADILAdial Pharmaceuticals-4.06%-4.31%-4.33%-15.91%-44.99%CYCCCyclacel Pharmaceuticals+3.06%+13.72%-60.08%-68.91%-94.97%GLMDGalmed Pharmaceuticals+0.70%+3.60%+10.77%-33.76%-66.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AADILAdial Pharmaceuticals2.7874 of 5 stars3.83.00.00.03.00.01.3CYCCCyclacel Pharmaceuticals1.4454 of 5 stars0.05.00.00.03.61.70.0GLMDGalmed Pharmaceuticals1.4689 of 5 stars0.04.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRXAcelRx Pharmaceuticals 0.00N/AN/AN/AADILAdial Pharmaceuticals 3.50Strong Buy$8.001,111.94% UpsideCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AGLMDGalmed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ADIL, GLMD, ACRX, and CYCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRXAcelRx Pharmaceuticals$1.77M0.00N/AN/A$2.65 per share0.00ADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/ACYCCCyclacel Pharmaceuticals$14K1,813.55N/AN/A$0.57 per share2.89GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$33.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRXAcelRx Pharmaceuticals$47.76M-$2.23N/AN/AN/AN/A-81.54%-46.02%N/AADILAdial Pharmaceuticals-$5.12M-$1.46N/AN/AN/AN/A-168.25%-148.46%8/12/2025 (Estimated)CYCCCyclacel Pharmaceuticals-$22.56M-$56.00N/A∞N/A-18,150.00%-1,901.11%-188.23%6/3/2025 (Estimated)GLMDGalmed Pharmaceuticals-$6.91M-$16.66N/A∞N/AN/A-28.75%-24.98%N/ALatest ADIL, GLMD, ACRX, and CYCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q1 2025CYCCCyclacel Pharmaceuticals-$0.29-$0.33-$0.04N/A$0.03 millionN/A5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/14/2025Q1 2025ADILAdial Pharmaceuticals-$0.50-$0.34+$0.16-$0.34N/AN/A4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$4.64-$5.28-$0.64-$0.33$0.01 million$0.01 million3/4/2025Q4 2024ADILAdial Pharmaceuticals-$0.38-$0.15+$0.23-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/AADILAdial PharmaceuticalsN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals$0.159.10%N/AN/A N/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ALatest ADIL, GLMD, ACRX, and CYCC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$2.404/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRXAcelRx PharmaceuticalsN/A4.044.04ADILAdial PharmaceuticalsN/A6.786.78CYCCCyclacel PharmaceuticalsN/A0.770.77GLMDGalmed PharmaceuticalsN/A7.037.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRXAcelRx Pharmaceuticals19.79%ADILAdial Pharmaceuticals16.41%CYCCCyclacel Pharmaceuticals23.58%GLMDGalmed Pharmaceuticals76.14%Insider OwnershipCompanyInsider OwnershipACRXAcelRx Pharmaceuticals3.00%ADILAdial Pharmaceuticals5.24%CYCCCyclacel Pharmaceuticals68.00%GLMDGalmed Pharmaceuticals19.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRXAcelRx Pharmaceuticals1916.95 million16.44 millionOptionableADILAdial Pharmaceuticals207.90 million6.07 millionNo DataCYCCCyclacel Pharmaceuticals1415.40 million4.78 millionOptionableGLMDGalmed Pharmaceuticals201.65 million516,000Not OptionableADIL, GLMD, ACRX, and CYCC HeadlinesRecent News About These CompaniesGalmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASHMay 27, 2025 | prnewswire.comGALMED PHARMACEUTICALS Earnings Results: $GLMD Reports Quarterly EarningsMay 24, 2025 | nasdaq.comGalmed Pharmaceuticals (NASDAQ:GLMD) Rating Increased to Sell at Wall Street ZenMay 24, 2025 | americanbankingnews.comGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 22, 2025 | finanznachrichten.deGalmed Pharmaceuticals: Q1 Earnings SnapshotMay 22, 2025 | houstonchronicle.comGalmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 22, 2025 | prnewswire.comGalmed Pharmaceuticals Ltd.: Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC ModelsMay 13, 2025 | finanznachrichten.deGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC ModelsMay 13, 2025 | finance.yahoo.comGalmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’May 7, 2025 | msn.comGalmed Pharmaceuticals Ltd.: Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly EnhancesMay 6, 2025 | finanznachrichten.deGalmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsMay 6, 2025 | prnewswire.comAnalysts Conflicted on These Healthcare Names: Galmed Pharmaceuticals (GLMD) and Regeneron (REGN)April 30, 2025 | theglobeandmail.comGalmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual FormulationApril 28, 2025 | prnewswire.comGalmed launches VCU collaboration to tackle drug resistance in GI cancersApril 19, 2025 | markets.businessinsider.comGalmed partners with VCU to target drug resistanceApril 17, 2025 | thepharmaletter.comGalmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI CancersApril 17, 2025 | prnewswire.comGalmed Pharmaceuticals Ltd.: Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 InhibitorApril 16, 2025 | finanznachrichten.deGalmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 InhibitorApril 15, 2025 | prnewswire.comGalmed Reports Positive Part 1 Results From AM-001 Study Of Aramchol Meglumine - Quick FactsApril 12, 2025 | nasdaq.comGalmed’s Aramchol Meglumine shows improved results in Part 1 of AM-001 studyApril 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADIL, GLMD, ACRX, and CYCC Company DescriptionsAcelRx Pharmaceuticals NASDAQ:ACRXAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.Adial Pharmaceuticals NASDAQ:ADIL$0.66 -0.03 (-4.06%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.67 +0.01 (+1.95%) As of 05/30/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Cyclacel Pharmaceuticals NASDAQ:CYCC$1.65 +0.05 (+3.06%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.70 +0.05 (+3.09%) As of 05/30/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Galmed Pharmaceuticals NASDAQ:GLMD$1.44 +0.01 (+0.70%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.44 0.00 (-0.07%) As of 05/30/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
